Home > Insider Trading > Filing (0001123292-14-000778)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1437786	Immune Design Corp.	IMDZ	Pharmaceutical Preparations (2834)	262007174

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198321	Farah Champsi	One Embacadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1198325	Daniel Janney	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1198330	P Guy Nohra	One Embacadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1399763	Alta Partners Viii, L.p.	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1399894	Alta Partners Management Viii, Llc	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-07-29	733,943	$0.00	733,943	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	531,843	$0.00	1,265,786	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	611,620	$0.00	1,877,406	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	305,810	$0.00	2,183,216	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	299,559	$12.00	2,482,775	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-07-29	733,943	$0.00	733,943	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-07-29	531,843	$0.00	531,843	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-07-29	611,620	$0.00	611,620	$0.00
Series C Preferred Stock	Series C Preferred Stock Warrant (right to buy)	Disposition	2014-07-29	305,810	$0.00	305,810	$8.18
Common Stock	Series C Preferred Stock	Acquisiton	2014-07-29	305,810	$0.00	305,810	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-07-29	305,810	$0.00	305,810	$0.00

Remaning Holdings	Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Direct
0		No	4	C	Direct
0		No	4	C	Direct
0	2013-10-16	No	4	X	Direct
305,810		No	4	X	Direct
0		No	4	C	Direct

Footnotes

Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.
The securities are held of record by Alta Partners VIII, L.P. ("APVIII"). Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of patient recruitment for specified studies or trials by the Issuer, (c) a liquidation event of the Issuer or (d) the closing of the Issuer's initial public offering.